An integrated systems genetics screen reveals the transcriptional structure of inherited predisposition to metastatic disease

Genome Research

Volumn 24, Issue 2, 2014, Pages 227-240

  Faraji, Farhoud ^a,b,c   Hu, Ying ^a   Wu, Gang ^d   Goldberger, Natalie E ^a   Walker, Renard C ^a   Zhang, Jinghui ^d   Hunter, Kent W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENETICS; CANCER SUSCEPTIBILITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; METASTASIS; METASTASIS FREE SURVIVAL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RNA SEQUENCE; TUMOR GROWTH;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICRORNAS; NEOPLASM METASTASIS; NEOPLASMS; QUANTITATIVE TRAIT LOCI; REPRESSOR PROTEINS; RNA, MESSENGER;

EID: 84893669890     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.166223.113     Document Type: Article

References (93)

1. Ahn HW, Morin RD, Zhao H, Harris RA, Coarfa C, Chen ZJ, Milosavljevic A, Marra MA, Rajkovic A. 2010. MicroRNA transcriptome in the newborn mouse ovaries determined by massive parallel sequencing. Mol Hum Reprod 16: 463-471.
2. Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, Sarkar FH. 2012. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol 227: 3373-3380.
3. Alsarraj J, Walker RC, Webster JD, Geiger TR, Crawford NP, Simpson RM, Ozato K, Hunter KW. 2011. Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-tomesenchymal transition-and stem cell-like conversion. Cancer Res 71: 3121-3131.
4. Aslakson CJ, Miller FR. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
5. Bao L,Hazari S,Mehra S, KaushalD,Moroz K,Dash S. 2012. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180: 2490-2503.
6. Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E. 2006. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 20: 1885-1898.
7. Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, et al. 2013. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat 137: 373-382.
8. Broman KW, Wu H, Sen S, Churchill GA. 2003. R/qtl: QTL mapping in experimental crosses. Bioinformatics 19: 889-890.
9. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, BerrettiniW, et al. 2004. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 36: 1133-1137.
10. Collart MA, Panasenko OO. 2012. The Ccr4-Not complex. Gene 492: 42-53.
11. Collart MA, Struhl K. 1994. NOT1(CDC39), NOT2(CDC36), NOT3, and NOT4 encode a global-negative regulator of transcription that differentially affects TATA-element utilization. Genes Dev 8: 525-537.
12. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. 2006. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 8: R16.
13. Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, Lukes L, Rowe WL, Zhang J, Ambs S, et al. 2007. Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 3: e214.
14. Crawford NP, Alsarraj J, Lukes L,Walker RC, Officewala JS, Yang HH, LeeMP, Ozato K, Hunter KW. 2008a. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci 105: 6380-6385.
15. Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW. 2008b. The Diasporin Pathway: A tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis 25: 357-369.
16. Das TK, Sangodkar J, Negre N, Narla G, Cagan RL. 2013. Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene 32: 3184-3197.
17. Deng M, Tang H, Zhou Y, Zhou M, XiongW, Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, et al. 2011. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci 124: 2997-3005.
18. Doss S, Schadt EE, Drake TA, Lusis AJ. 2005. Cis-acting expression quantitative trait loci in mice. Genome Res 15: 681-691.
19. Ein-Dor L, Zuk O, Domany E. 2006. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci 103: 5923-5928.
20. Ezzeddine N,Chang TC, ZhuW, YamashitaA,ChenCY, Zhong Z,YamashitaY, Zheng D, Shyu AB. 2007. Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol 27: 7791-7801.
21. Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L, Hunter KW. 2012. Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet 8: e1002926.
22. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, HafnerM, Reyal F, van Kouwenhove M, et al. 2011. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 71: 4443-4453.
23. Feinberg AP, Vogelstein B. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92.
24. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
25. Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA. 1999. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer 80: 1312-1321.
26. Goldberger N, Walker RC, Kim CH, Winter S, Hunter KW. 2013. Inherited variation inmiR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b. Cancer Res 73: 2671-2681.
27. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
28. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. 2006. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144.
29. Guy CT, Cardiff RD, Muller WJ. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
30. Haga CL, Phinney DG. 2012. MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network. J Biol Chem 287: 42695-42707.
31. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, Valsesia A, Ye Z, Kuan S, Edsall LE, et al. 2012. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res 22: 246-258.
32. Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW. 2009. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: A prognosis study. Breast Cancer Res 11: R75.
33. Hu Y, Wu G, Rusch M, Lukes L, Buetow KH, Zhang J, Hunter KW. 2012. Integrated cross-species transcriptional network analysis of metastatic susceptibility. Proc Natl Acad Sci 109: 3184-3189.
34. Hu Y, Bai L, Geiger T, Goldberger N, Walker RC, Green JE, Wakefield LM, Hunter KW. 2013. Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments. PLoS ONE 8: e72287.
35. Hui AB, Lin A, XuW,Waldron L, Perez-Ordonez B,Weinreb I, ShiW, Bruce J, Huang SH, O'Sullivan B, et al. 2013. Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res 19: 2154-2162.
36. Hunter KW, Broman KW, Voyer TL, Lukes L, Cozma D, Debies MT, Rouse J, Welch DR. 2001. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 61: 8866-8872.
37. Hurst DR, Edmonds MD, Welch DR. 2009. Metastamir: The field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495-7498.
38. Ito K, Inoue T, Yokoyama K, Morita M, Suzuki T, Yamamoto T. 2011. CNOT2 depletion disrupts and inhibits the CCR4-NOT deadenylase complex and induces apoptotic cell death. Genes Cells 16: 368-379.
39. Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gumus ZH, Lipkin SM. 2012. miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov 2: 540-553.
40. Jayne S, Zwartjes CG, van Schaik FM, Timmers HT. 2006. Involvement of the SMRT/NCoR-HDAC3 complex in transcriptional repression by theCNOT2 subunit of the human Ccr4-Not complex. Biochem J 398: 461-467.
41. Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, Asea A. 2012. A mouse model for triple-negative breast cancer tumorinitiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer 12: 120.
42. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152.
43. Kruk JA, Dutta A, Fu J, Gilmour DS, Reese JC. 2011. The multifunctional Ccr4-Not complex directly promotes transcription elongation. Genes Dev 25: 581-593.
44. Kuo YZ, Tai YH, Lo HI, Chen YL, Cheng HC, Fang WY, Lin SH, Yang CL, Tsai ST, Wu LW. 2013. MiR-99a exerts anti-metastasis through inhibiting myotubularin-related protein 3 expression in oral cancer. Oral Dis. doi: 10.1111/odi.12133.
45. Lancaster M, Rouse J, Hunter KW. 2005. Modifiers of mammary tumor progression and metastasis on mouse chromosomes 7, 9, and 17. Mamm Genome 16: 120-126.
46. Langfelder P, Horvath S. 2008. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics 9: 559.
47. Lau NC, Kolkman A, van Schaik FM, Mulder KW, Pijnappel WW, Heck AJ, Timmers HT. 2009. Human Ccr4-Not complexes contain variable deadenylase subunits. Biochem J 422: 443-453.
48. Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
49. Li A, Horvath S. 2009. Network module detection: Affinity search technique with the multi-node topological overlap measure. BMC Res Notes 2: 142.
50. Li Y, Zhang M, Chen H, Dong Z, Ganapathy V, Thangaraju M, Huang S. 2010. Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Res 70: 7894-7904.
51. Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, Liang S, Lu S, Liu Y, Zhang J, et al. 2013a. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis 34: 2145-2155.
52. Li H, Zhao J, Zhang JW, Huang QY, Huang JZ, Chi LS, Tang HJ, Liu GQ, Zhu DJ, Ma WM. 2013b. MicroRNA-217, down-regulated in clear cell renal cell carcinoma and associated with lower survival, suppresses cell proliferation and migration. Neoplasma 60: 511-515.
53. Li J, Song Y, Wang Y, Luo J, Yu W. 2013c. MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem 380: 277-282.
54. Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, Lobie PE, Zhu T. 2013d. c-MYCregulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem 288: 18121-18133.
55. Liang S, He L, Zhao X, Miao Y, Gu Y, Guo C, Xue Z, DouW, Hu F,Wu K, et al. 2011. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS ONE 6: e18409.
56. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW. 1998. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77: 640-644.
57. Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, Yagita H, Lindeman GJ, Smyth GK, Visvader JE. 2010. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 12: R21.
58. Liu CJ, ShenWG, Peng SY, Cheng HW, Kao SY, Lin SC, Chang KW. 2013. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int J Cancer 134: 811-821.
59. Lukes L, Crawford NP, Walker R, Hunter KW. 2009. The origins of breast cancer prognostic gene expression profiles. Cancer Res 69: 310-318.
60. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. 1998. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153: 865-873.
61. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. 2006. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217.
62. Mucenski ML, Taylor BA, Jenkins NA, Copeland NG. 1986. AKXD recombinant inbred strains: Models for studying the molecular genetic basis of murine lymphomas. Mol Cell Biol 6: 4236-4243.
63. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW. 2005. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 37: 1055-1062.
64. Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, Russell R, Johnson MD, Dickson RB. 2004. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev Biol Anim 40: 14-21.
65. Pencheva N, Tavazoie SF. 2013. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 15: 546-554.
66. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, RossDT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human breast tumours. Nature 406: 747-752.
67. Pillutla RC, Yue Z, Maldonado E, Shatkin AJ. 1998. Recombinant human mRNA cap methyltransferase binds capping enzyme/RNA polymerase IIo complexes. J Biol Chem 273: 21443-21446.
68. Quigley DA, To MD, Perez-Losada J, Pelorosso FG, Mao JH, Nagase H, Ginzinger DG, Balmain A. 2009. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature 458: 505-508.
69. Ramaswamy S, Ross KN, Lander ES, Golub TR. 2003. A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
70. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. 2011. GOBO: Gene expression-based outcome for breast cancer online. PLoS ONE 6: e17911.
71. Rutnam ZJ, Yang BB. 2012. The non-coding 39UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci 125: 2075-2085.
72. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V, Ruff TG, Milligan SB, Lamb JR, Cavet G, et al. 2003. Genetics of gene expression surveyed in maize, mouse and man. Nature 422: 297-302.
73. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M. 2008. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413.
74. Su J, Shao X, Liu H, Liu S, Wu Q, Zhang Y. 2012. Genome-wide dynamic changes of DNA methylation of repetitive elements in human embryonic stem cells and fetal fibroblasts. Genomics 99: 10-17.
75. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550.
76. Takagaki Y, Manley JL. 2000. Complex protein interactions within the human polyadenylation machinery identify a novel component. Mol Cell Biol 20: 1515-1525.
77. Takahashi F, Chiba N, Tajima K, Hayashida T, Shimada T, Takahashi M, Moriyama H, Brachtel E, Edelman EJ, Ramaswamy S, et al. 2011. Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30: 3084-3095.
78. Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM. 1999. Systematic determination of genetic network architecture. Nat Genet 22: 281-285.
79. Tavazoie SF, Alarcon C, Oskarsson T, Padua D,Wang Q, Bos PD, Gerald WL, Massague J. 2008. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152.
80. Uchino K, Takeshita F, Takahashi RU, Kosaka N, Fujiwara K, Naruoka H, Sonoke S, Yano J, Sasaki H, Nozawa S et al. 2013. Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther 21: 610-619.
81. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM,Wang ZC, Brock JE, Richardson AL, Weinberg RA. 2009. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046.
82. Valencia K, Martin-Fernandez M, Zandueta C, Ormazabal C, Martinez-Canarias S, Bandres E, de la Piedra C, Lecanda F. 2013. miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. Bone 52: 532-539.
83. van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. 2002. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
84. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,Witteveen AT, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
85. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. 2005. Geneexpression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
86. Winter SF, Lukes L,Walker RC,Welch DR, HunterKW. 2012. Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis. PLoS Genet 8: e1002735.
87. Witkos TM, Koscianska E, Krzyzosiak WJ. 2011. Practical aspects of microRNA target prediction. Curr Mol Med 11: 93-109.
88. Yang H, Crawford N, Lukes L, Finney R, Lancaster M, Hunter KW. 2005. Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 22: 593-603.
89. Yang H, Fang F, Chang R, Yang L. 2013a. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor b receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58: 205-217.
90. Yang Z, Zhang Y,Wang L. 2013b. A feedback inhibition between miRNA-127 and TGFb/c-Jun cascade in HCC cell migration via MMP13. PLoS ONE 8: e65256.
91. Ying Q, Liang L, GuoW, Zha R, Tian Q, Huang S, Yao J, Ding J, Bao M, Ge C, et al. 2011. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 54: 2064-2075.
92. Zheng X, Dumitru R, Lackford BL, Freudenberg JM, Singh AP, Archer TK, Jothi R, Hu G. 2012. Cnot1, Cnot2, and Cnot3 maintain mouse and human ESC identity and inhibit extraembryonic differentiation. Stem Cells 30: 910-922.
93. Zhou J,WangW. 2011. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol 104: 278-283.